drugset / Trial / NCT06569472
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).
Timeline
- Start
- 2024-07-02
- Primary completion
- 2027-07-31
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-targetd CAR-T | Cell therapy | — | Intravenous |